Report an error

Spotted something inaccurate in “New GLP-1 Drug TE-8105 Achieves 120-Hour Half-Life in Phase 1 Trial, Supporting Potential Biweekly Dosing”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.